XNAS · PHARMACEUTICAL PREPARATIONS · PHARMACEUTICAL PREPARATIONS
Includes notes from domestic 8-K and foreign private issuer 6-K disclosures.
Vertex Pharmaceuticals (VRTX) had 1 Form 144 pre-sale notice filed on 2026-05-06. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction.
Vertex Pharmaceuticals (VRTX) had 1 Form 144 pre-sale notice filed on 2026-06-26. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least …
Vertex Pharmaceuticals (VRTX) had 1 Form 144 pre-sale notice filed on 2026-06-15. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least …
Vertex Pharmaceuticals (VRTX) had 1 Form 144 pre-sale notice filed on 2026-06-18. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least …
Vertex Pharmaceuticals (VRTX) had 1 Form 144 pre-sale notice filed on 2026-06-05. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least …
Vertex Pharmaceuticals (VRTX) had 1 Form 144 pre-sale notice filed on 2026-06-01. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least …
Vertex Pharmaceuticals (VRTX) had 1 Form 144 pre-sale notice filed on 2026-05-29. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least …
Vertex Pharmaceuticals (VRTX) had 1 Form 144 pre-sale notice filed on 2026-05-12. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least …
Vertex Pharmaceuticals (VRTX) had 2 Form 144 pre-sale notices filed on 2026-05-15. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least…
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 6/18/2026 | Bozic Carmen | EVP and CMO | SELL | -1,020 | $462 | $471,413 |
| 6/15/2026 | Bozic Carmen | EVP and CMO | SELL | -4,062 | $450 | $1,827,900 |
| 6/5/2026 | Bozic Carmen | EVP and CMO | SELL | -1,745 | $450 | $785,250 |
| 6/1/2026 | Liu Joy | EVP and Chief Legal Officer | SELL | -828 | $440 | $364,245 |
| 5/29/2026 | Bozic Carmen | EVP and CMO | SELL | -1,974 | $450 | $888,300 |
| 5/15/2026 | Bunnage Mark E. | EVP, Chief Scientific Officer | SELL | -33 | $453 | $14,964 |
| 5/15/2026 | Bozic Carmen | EVP and CMO | SELL | -1,354 | $453 | $613,971 |
| 5/12/2026 | Bozic Carmen | EVP and CMO | SELL | -6,988 | $450 | $3,144,600 |
| 5/4/2026 | Bhatia Sangeeta N. | — | SELL | -318 | $424 | $134,746 |
| 5/1/2026 | Upadhyay Suketu | — | DISPOSITION | -796 | — | — |
| 5/1/2026 | Upadhyay Suketu | — | GRANT | 2,866 | — | — |
| 5/1/2026 | Upadhyay Suketu | — | GRANT | 796 | — | — |
| 5/1/2026 | Thornberry Nancy | — | GRANT | 472 | — | — |
| 5/1/2026 | Thornberry Nancy | — | DISPOSITION | -398 | — | — |
| 5/1/2026 | Thornberry Nancy | — | GRANT | 1,433 | — | — |
| 5/1/2026 | Thornberry Nancy | — | GRANT | 398 | — | — |
| 5/1/2026 | Schneider Jennifer | — | GRANT | 472 | — | — |
| 5/1/2026 | Schneider Jennifer | — | DISPOSITION | -796 | — | — |
| 5/1/2026 | Schneider Jennifer | — | GRANT | 1,433 | — | — |
| 5/1/2026 | Schneider Jennifer | — | GRANT | 796 | — | — |
| Date | Filer | Relationship | Est. shares | Filing |
|---|---|---|---|---|
| 6/26/2026 | Bozic Carmen | — | 596 | SEC |
| 6/18/2026 | Bozic Carmen | — | 1,020 | SEC |
| 6/15/2026 | Bozic Carmen | — | 4,062 | SEC |
| 6/5/2026 | Bozic Carmen | — | 1,745 | SEC |
| 6/1/2026 | Liu Joy | — | 828 | SEC |
| 5/29/2026 | Bozic Carmen | — | 1,974 | SEC |
| 5/15/2026 | Bunnage Mark E. | — | 33 | SEC |
| 5/15/2026 | Bozic Carmen | — | 1,354 | SEC |
| 5/12/2026 | Bozic Carmen | — | 6,988 | SEC |
| 5/6/2026 | Biller Jonathan | — | 5,193 | SEC |
| Institution | Shares | Value ($) | Change % | Filing date |
|---|---|---|---|---|
| Vanguard Group | 24,105,823 | $10,928,615,915 | — | 1/29/2026 |
| BlackRock | 21,312,244 | $9,989,475,160 | — | 8/13/2024 |
| State Street | 11,689,539 | $5,299,569,401 | — | 2/13/2026 |
| JP Morgan Chase | 6,141,281 | $2,784,211,285 | — | 2/11/2026 |
| Fidelity (FMR) | 2,212,596 | $1,003,101,845 | — | 2/17/2026 |
| Citadel Advisors | 789,960 | $358,136,266 | — | 2/17/2026 |
| Millennium Management | 487,964 | $221,223,359 | — | 2/17/2026 |
| AQR Capital | 143,651 | $65,125,669 | — | 2/17/2026 |
| DE Shaw | 42,500 | $19,267,800 | — | 2/17/2026 |
| Point72 | 28,100 | $12,739,416 | — | 2/17/2026 |
| Bridgewater Associates | 27,488 | $12,461,960 | — | 2/13/2026 |
| Two Sigma | 4,155 | $1,883,711 | — | 2/17/2026 |